Yervoy Off to Strong Start, Says BMS' Tony Hooper
This article was originally published in The Pink Sheet Daily
Executive Summary
The launch of Bristol's metastatic melanoma therapy is off to a strong start, but uncertainties linger, including whether the drug will compete with Roche's BRAF inhibitor.